We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Emergent Biosolutions Inc | NYSE:EBS | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.0499 | -2.56% | 1.9001 | 2.01 | 1.90 | 2.00 | 875,929 | 00:58:23 |
From Apr 2022 to Apr 2024
By Colin Kellaher
Emergent BioSolutions Inc. on Friday said the Food and Drug Administration accepted for review its application seeking approval of its anthrax vaccine candidate AV7909.
The Gaithersburg, Md., maker of vaccines and therapeutics, which has spent two decades working with the U.S. government on its anthrax program, is studying the vaccine for post-exposure prevention of disease following suspected or confirmed exposure in people ages 18 through 65 when administered in conjunction with recommended antibacterial drugs.
Emergent said the FDA set a target action date for a decision in April 2023.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 24, 2022 06:58 ET (10:58 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Emergent Biosolutions Chart |
1 Month Emergent Biosolutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
